U.S. FTC Seeks More Data About Aussie CSL Buy Of Talecris
This article was originally published in PharmAsia News
The U.S. Federal Trade Commission has requested more information from Australia's CSL about its bid to take over Talecris Biotherapeutics of the United States. CSL, the world's largest maker of plasma products, said such a request was common for mergers that could have U.S. antitrust implications. CSL, which has proposed buying Talecris for $2 billion, said both firms are cooperating with the FTC as it considers the buyout. (Click here for more
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.